Hainan Honz Pharmaceutical Co - Asset Resilience Ratio
Hainan Honz Pharmaceutical Co (300086) has an Asset Resilience Ratio of 0.27% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300086 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2019)
This chart shows how Hainan Honz Pharmaceutical Co's Asset Resilience Ratio has changed over time. See 300086 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hainan Honz Pharmaceutical Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300086 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥7.01 Million | 0.27% |
| Total Liquid Assets | CN¥7.01 Million | 0.27% |
Asset Resilience Insights
- Limited Liquidity: Hainan Honz Pharmaceutical Co maintains only 0.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Honz Pharmaceutical Co Industry Peers by Asset Resilience Ratio
Compare Hainan Honz Pharmaceutical Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Hainan Honz Pharmaceutical Co (2014–2019)
The table below shows the annual Asset Resilience Ratio data for Hainan Honz Pharmaceutical Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.94% | CN¥20.53 Million ≈ $3.00 Million |
CN¥2.19 Billion ≈ $321.11 Million |
+0.30pp |
| 2017-12-31 | 0.63% | CN¥14.15 Million ≈ $2.07 Million |
CN¥2.24 Billion ≈ $327.19 Million |
-0.71pp |
| 2016-12-31 | 1.34% | CN¥29.36 Million ≈ $4.30 Million |
CN¥2.19 Billion ≈ $320.39 Million |
-44.24pp |
| 2015-12-31 | 45.58% | CN¥952.50 Million ≈ $139.38 Million |
CN¥2.09 Billion ≈ $305.81 Million |
+42.98pp |
| 2014-12-31 | 2.59% | CN¥50.00 Million ≈ $7.32 Million |
CN¥1.93 Billion ≈ $282.00 Million |
-- |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face ma… Read more